Public health agency The US Food and Drug Administration on Monday announced the approval of the first generic version of Sabril (vigabatrin) in 500mg tablets for treating complex partial seizures, also called focal seizures, in patients ten years and older.
This US FDA's approval of generic vigabatrin tablets was granted to Teva Pharmaceuticals USA.
The agency has approved the first generic version of Sabril (vigabatrin) in 500mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients ten years and older who have responded inadequately to several alternative (refractory) treatments.
Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness. Typically, complex partial seizures last between 30 and 90 seconds and are often followed by a period of disorientation, confusion and/or fatigue.
Teva's generic vigabatrin tablets is part of a single shared-system Risk Evaluation and Mitigation Strategy (REMS) programme with other drug products containing vigabatrin to ensure safe use of the product under the US FDA's requirement.
Bonesupport gains FDA clearance for CERAMENT G in open fractures
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA